Drug
Immune checkpoint inhibitor (ICI)
Immune checkpoint inhibitor (ICI) is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(2)
Detailed Status
Not yet recruiting2
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
not_yet_recruiting240%
recruiting120%
completed240%
Recent Activity
1 active trials
Showing 5 of 5
not_yet_recruitingphase_2
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
NCT07572864
not_yet_recruitingphase_2
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
NCT07064668
recruitingphase_1
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
NCT06063681
completedphase_1
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
NCT04020185
completed
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
NCT04898751
Clinical Trials (5)
Showing 5 of 5 trials
NCT07572864Phase 2
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
NCT07064668Phase 2
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
NCT06063681Phase 1
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
NCT04020185Phase 1
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
NCT04898751
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5